Adverse events · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found